Kevin Doe's Album: Wall Photos
Antibody drug
conjugates market is estimated to be worth more than 15 billion in 2030,
predicts Roots Analysis
Report Keywords –
Antibody Drug, Conjugates, Roots Analysis, Biotech, Analysis
Antibody drug conjugates (ADCs) represent a transformative
approach to modern cancer treatment; over the years, this upcoming class of
targeted therapeutic agents has generated significant enthusiasm within the
medical science community
Roots Analysis is pleased to announce the publication of its recent
study, titled, “ Antibody Drug Conjugates Market
(5th Edition), 2019-2030.”
The report features an extensive study of the current
market landscape, offering an informed opinion on the likely adoption of these
therapeutics over the next decade. It features an in-depth analysis, highlighting
the capabilities of various stakeholders engaged in this domain. In addition to
other elements, the study includes:
§
A
detailed
assessment of the current market landscape of ADCs.
§
Elaborate profiles of the clinical stage companies
(shortlisted based on phase of development of the lead drug) and their
respective product portfolios.
§
An analysis of the most commonly targeted therapeutic
indications and details of ADC candidates being developed against them,
highlighting key epidemiological facts about the diseases and currently
available treatment options, other than ADCs.
§
A list of key opinion leaders (KOLs) within this domain.
§
An insightful competitiveness analysis of biological
targets.
§
An analysis of the partnerships that have been established
in the recent past.
§
An analysis of the
investments made.
§
A study of the various grants that have been awarded to
research institutes engaged in projects related to ADCs, between 2011 and 2019
(till April).
§
An elaborate discussion on the various strategies that can
be adopted by the drug developers across key commercialization stages, namely
prior to product launch, during / post launch.
§
An analysis of the key promotional strategies that have
been adopted by the developers of marketed products.
§
An assessment of the various therapeutics that are being
evaluated in combination with ADCs.
§
A review of the evolution of ADC conjugation technologies.
§
An overview of the studies conducted to better analyze
non-clinical data and support first-in-human (FIH) dose selection in ADCs.
§
An elaborate discussion on various factors that form the
basis for the pricing of ADC products.
§
A case study on manufacturing of ADCs, highlighting the key
challenges, and a list of contract service providers that are involved in this
domain.
§
A case study on companies offering companion diagnostics.
§
A detailed market forecast, featuring analysis of the
current and projected future opportunity across key market segments (listed
below)
To sample report – https://www.rootsanalysis.com/reports/270/request-sample.html
§
Type of payload
§
MMAE
§
DM4
§
Camptothecin
§
AM1
§
MMAF
§
Type of linker
§
VC
§
Sulfo-SPDB
§
SMCC
§
VA
§
Hydrazone linker
§
Others
§
Target Indications
§
Breast Cancer
§
Lymphoma
§
Leukemia
§
Urothelial cancer
§
Lung cancer
§
Ovaria cancer
§
Others
§
Target Antigen
§
CD30
§
HER2
§
CD22
§
CD33
§
Others
§
Small Molecule
§
Technology Providers
§
Seattle Genetics
§
ImmunoGen
§
StemCentRx
§
Immunomedics
§
Others
§
Key Geographies
§
North America
§
Europe
§
Asia Pacific
Transcripts of interviews held with the
following senior level representatives of stakeholder companies:
§
Alan Burnett (Professor, School of Medicine, Cardiff
University)
§
Aldo Braca (President and Chief Executive Officer) and
Giorgio Salciarini (Technical Business Development Senior Manager, BSP
Pharmaceuticals)
§
Anthony DeBoer (Director, Business Development, Synaffix)
§
Christian Bailly (Director of CDMO, Pierre Fabre)
§
Christian Rohlff, (Chief Executive Officer and Founder,
Oxford BioTherapeutics)
§
Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
§
John Burt (Chief Executive Officer, Abzena)
§
Jennifer L. Mitcham (Director, SMARTag ADCs and
Bioconjugates) and Stacy McDonald (Group Product Manager, Catalent Pharma
Solutions)
§
Laurent Ducry (Head of Bioconjugates Commercial
Development, Lonza)
§
Mark Wright (Site Head, Piramal Healthcare)
§
Sasha Koniev (Chief Executive Officer & Co-Founder,
Syndivia)
§
Tatsuya Okuzumi (Associate General Manager, Ajinomoto
Bio-Pharma Services)
§
Toshimitsu Uenaka (Executive Director) and Takashi Owa
(Chief Innovation Officer, Eisai)
§
Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)
Key
companies covered in the report
§
Bristol Myers Squibb
§
AbbVie
§
Astellas Pharma
§
AstraZeneca
§
Daiichi Sankyo
§
Pfizer
§
Roche / Genentech
§
Synthon
§
Bayer HealthCare
§
Biotest Pharmaceuticals
For
more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Other Offerings
1.
ADC
Contract Manufacturing Market (3rd Edition), 2018-2030
2.
Gene
Therapy Market (3rd Edition), 2019 - 2030
3.
Global T-Cell
(CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
conjugates market is estimated to be worth more than 15 billion in 2030,
predicts Roots Analysis
Report Keywords –
Antibody Drug, Conjugates, Roots Analysis, Biotech, Analysis
Antibody drug conjugates (ADCs) represent a transformative
approach to modern cancer treatment; over the years, this upcoming class of
targeted therapeutic agents has generated significant enthusiasm within the
medical science community
Roots Analysis is pleased to announce the publication of its recent
study, titled, “ Antibody Drug Conjugates Market
(5th Edition), 2019-2030.”
The report features an extensive study of the current
market landscape, offering an informed opinion on the likely adoption of these
therapeutics over the next decade. It features an in-depth analysis, highlighting
the capabilities of various stakeholders engaged in this domain. In addition to
other elements, the study includes:
§
A
detailed
assessment of the current market landscape of ADCs.
§
Elaborate profiles of the clinical stage companies
(shortlisted based on phase of development of the lead drug) and their
respective product portfolios.
§
An analysis of the most commonly targeted therapeutic
indications and details of ADC candidates being developed against them,
highlighting key epidemiological facts about the diseases and currently
available treatment options, other than ADCs.
§
A list of key opinion leaders (KOLs) within this domain.
§
An insightful competitiveness analysis of biological
targets.
§
An analysis of the partnerships that have been established
in the recent past.
§
An analysis of the
investments made.
§
A study of the various grants that have been awarded to
research institutes engaged in projects related to ADCs, between 2011 and 2019
(till April).
§
An elaborate discussion on the various strategies that can
be adopted by the drug developers across key commercialization stages, namely
prior to product launch, during / post launch.
§
An analysis of the key promotional strategies that have
been adopted by the developers of marketed products.
§
An assessment of the various therapeutics that are being
evaluated in combination with ADCs.
§
A review of the evolution of ADC conjugation technologies.
§
An overview of the studies conducted to better analyze
non-clinical data and support first-in-human (FIH) dose selection in ADCs.
§
An elaborate discussion on various factors that form the
basis for the pricing of ADC products.
§
A case study on manufacturing of ADCs, highlighting the key
challenges, and a list of contract service providers that are involved in this
domain.
§
A case study on companies offering companion diagnostics.
§
A detailed market forecast, featuring analysis of the
current and projected future opportunity across key market segments (listed
below)
To sample report – https://www.rootsanalysis.com/reports/270/request-sample.html
§
Type of payload
§
MMAE
§
DM4
§
Camptothecin
§
AM1
§
MMAF
§
Type of linker
§
VC
§
Sulfo-SPDB
§
SMCC
§
VA
§
Hydrazone linker
§
Others
§
Target Indications
§
Breast Cancer
§
Lymphoma
§
Leukemia
§
Urothelial cancer
§
Lung cancer
§
Ovaria cancer
§
Others
§
Target Antigen
§
CD30
§
HER2
§
CD22
§
CD33
§
Others
§
Small Molecule
§
Technology Providers
§
Seattle Genetics
§
ImmunoGen
§
StemCentRx
§
Immunomedics
§
Others
§
Key Geographies
§
North America
§
Europe
§
Asia Pacific
Transcripts of interviews held with the
following senior level representatives of stakeholder companies:
§
Alan Burnett (Professor, School of Medicine, Cardiff
University)
§
Aldo Braca (President and Chief Executive Officer) and
Giorgio Salciarini (Technical Business Development Senior Manager, BSP
Pharmaceuticals)
§
Anthony DeBoer (Director, Business Development, Synaffix)
§
Christian Bailly (Director of CDMO, Pierre Fabre)
§
Christian Rohlff, (Chief Executive Officer and Founder,
Oxford BioTherapeutics)
§
Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
§
John Burt (Chief Executive Officer, Abzena)
§
Jennifer L. Mitcham (Director, SMARTag ADCs and
Bioconjugates) and Stacy McDonald (Group Product Manager, Catalent Pharma
Solutions)
§
Laurent Ducry (Head of Bioconjugates Commercial
Development, Lonza)
§
Mark Wright (Site Head, Piramal Healthcare)
§
Sasha Koniev (Chief Executive Officer & Co-Founder,
Syndivia)
§
Tatsuya Okuzumi (Associate General Manager, Ajinomoto
Bio-Pharma Services)
§
Toshimitsu Uenaka (Executive Director) and Takashi Owa
(Chief Innovation Officer, Eisai)
§
Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)
Key
companies covered in the report
§
Bristol Myers Squibb
§
AbbVie
§
Astellas Pharma
§
AstraZeneca
§
Daiichi Sankyo
§
Pfizer
§
Roche / Genentech
§
Synthon
§
Bayer HealthCare
§
Biotest Pharmaceuticals
For
more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Other Offerings
1.
ADC
Contract Manufacturing Market (3rd Edition), 2018-2030
2.
Gene
Therapy Market (3rd Edition), 2019 - 2030
3.
Global T-Cell
(CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis